Startup · $8m raised
Delivers personalised therapeutic ultrasound for Alzheimer's disease
Brisbane, QLD
Every investor coverage indicates participated in a round Ceretas raised.
| Investor | Rounds | Invested |
|---|---|---|
| Clem Jones Group | Unnamed stage | - |
The transaction that ended Ceretas's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | 13 Jul 2026 | $8m | Dealroom (16 Sep 2026), kalkine.com.au, Dealroom (13 Jul 2026) |
Companies Ceretas acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Rachel de las Heras | Chief Executive Officer and Managing Director | Dealroom, Startup Daily |
| John Keep | Chairman | sharecafe.com.au |
| Tony Keating | Executive Director | sharecafe.com.au |
Stories naming Ceretas. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian medtech Ceretas hit a milestone in its CUREator+ program, unlocking the final instalment of a government-funded grant; the piece also recaps its A$8 million IPO and ASX listing earlier in 2026.
UQ medtech spin-out Ceretas sold its IPO, raising about $8 million, and now targets a fast-tracked ASX debut; the article also recalls ResApp's 2022 acquisition by Pfizer.
Also kalkine.com.au·Dealroom
Ceretas, a university spin-off, has sold A$8 million of shares in a stockmarket float valuing the ultrasound medtech at A$18 million, with the proceeds going toward device trials.
Also kalkine.com.au·Dealroom
Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.